PH12016501769A1 - Treatment of intrahepatic cholestatic diseases - Google Patents
Treatment of intrahepatic cholestatic diseasesInfo
- Publication number
- PH12016501769A1 PH12016501769A1 PH12016501769A PH12016501769A PH12016501769A1 PH 12016501769 A1 PH12016501769 A1 PH 12016501769A1 PH 12016501769 A PH12016501769 A PH 12016501769A PH 12016501769 A PH12016501769 A PH 12016501769A PH 12016501769 A1 PH12016501769 A1 PH 12016501769A1
- Authority
- PH
- Philippines
- Prior art keywords
- treatment
- intrahepatic cholestatic
- cholestatic diseases
- diseases
- intrahepatic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968037P | 2014-03-20 | 2014-03-20 | |
| PCT/US2015/021502 WO2015143178A1 (en) | 2014-03-20 | 2015-03-19 | Treatment of intrahepatic cholestatic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12016501769B1 PH12016501769B1 (en) | 2017-01-09 |
| PH12016501769A1 true PH12016501769A1 (en) | 2017-01-09 |
Family
ID=52808186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12016501769A PH12016501769A1 (en) | 2014-03-20 | 2016-09-08 | Treatment of intrahepatic cholestatic diseases |
Country Status (32)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5694941B2 (ja) | 2008-10-17 | 2015-04-01 | シーマベイ セラピューティクス，インコーポレイティド | 小型高密度ｌｄｌ粒子を減少させる方法 |
| US10272058B2 (en) * | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| CA2944139C (en) | 2014-04-11 | 2020-11-03 | Cymabay Therapeutics, Inc. | Treatment of nafld and nash |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| JP7023371B2 (ja) * | 2017-09-26 | 2022-02-21 | サイマベイ・セラピューティクス・インコーポレイテッド | 胆汁うっ滞性そう痒の処置 |
| WO2020102351A1 (en) * | 2018-11-16 | 2020-05-22 | Cymabay Therapeutics, Inc. | Treatment of obesity and its complications |
| US12318357B2 (en) | 2019-08-02 | 2025-06-03 | Acelot, Inc. | Small molecule drugs and related methods for treatment of diseases related to TDP-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation |
| US20210145774A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of alcoholic liver disease |
| WO2021097034A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases |
| RS65546B1 (sr) | 2021-02-01 | 2024-06-28 | Cymabay Therapeutics Inc | Tretman holangiopatija sa seladelparom |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| DE69636160D1 (de) | 1995-03-06 | 2006-06-29 | Isis Pharmaceuticals Inc | Verfahren zur synthese von 2'-0-substituierten pyrimidinen und oligomere davon |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| DK0882061T3 (da) | 1996-02-14 | 2004-09-27 | Isis Pharmaceuticals Inc | Sukkermodificerede gapped oligonukleotider |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US7981915B2 (en) * | 2003-04-30 | 2011-07-19 | Beth Israel Deaconess Medical Center | Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene |
| UA87467C2 (xx) | 2003-09-19 | 2009-07-27 | Янссен Фармацевтика Н.В | 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги |
| PT1725234E (pt) | 2004-03-05 | 2013-03-04 | Univ Pennsylvania | Métodos com efeitos secundários reduzidos para tratamento de patologias ou doenças associadas a hiperlipidemia e hipercolesterolemia |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| JP5694941B2 (ja) | 2008-10-17 | 2015-04-01 | シーマベイ セラピューティクス，インコーポレイティド | 小型高密度ｌｄｌ粒子を減少させる方法 |
| SG183529A1 (en) | 2010-03-30 | 2012-10-30 | Novartis Ag | Uses of dgat1 inhibitors |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20160279085A1 (en) | 2013-11-20 | 2016-09-29 | Cymabay Therapeutics, Inc. | Treatment of Severe Hyperlipidemia |
| HK1224186A1 (zh) | 2013-11-20 | 2017-08-18 | Cymabay Therapeutics, Inc. | 纯阖家族型高胆固醇血症的治疗 |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| CA2944139C (en) | 2014-04-11 | 2020-11-03 | Cymabay Therapeutics, Inc. | Treatment of nafld and nash |
| CN106470675A (zh) | 2014-06-26 | 2017-03-01 | 西玛贝医药公司 | 严重高甘油三酯血症的治疗 |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| JP7023371B2 (ja) | 2017-09-26 | 2022-02-21 | サイマベイ・セラピューティクス・インコーポレイテッド | 胆汁うっ滞性そう痒の処置 |
| WO2020102351A1 (en) | 2018-11-16 | 2020-05-22 | Cymabay Therapeutics, Inc. | Treatment of obesity and its complications |
| MX2021005724A (es) | 2018-11-16 | 2021-07-21 | Cymabay Therapeutics Inc | Tratamiento combinado contra nafld y nash. |
-
2015
- 2015-03-19 ES ES15714132T patent/ES2701094T3/es active Active
- 2015-03-19 CA CA2941401A patent/CA2941401C/en active Active
- 2015-03-19 JP JP2017501116A patent/JP6568577B2/ja active Active
- 2015-03-19 LT LTEP15714132.6T patent/LT3119384T/lt unknown
- 2015-03-19 SI SI201530455T patent/SI3119384T1/sl unknown
- 2015-03-19 BR BR112016020260A patent/BR112016020260A8/pt not_active Application Discontinuation
- 2015-03-19 AU AU2015231232A patent/AU2015231232B2/en active Active
- 2015-03-19 MX MX2016012203A patent/MX367478B/es active IP Right Grant
- 2015-03-19 WO PCT/US2015/021502 patent/WO2015143178A1/en not_active Ceased
- 2015-03-19 HU HUE15714132A patent/HUE041733T2/hu unknown
- 2015-03-19 SM SM20180690T patent/SMT201800690T1/it unknown
- 2015-03-19 EA EA201691887A patent/EA032358B1/ru active IP Right Revival
- 2015-03-19 NZ NZ724057A patent/NZ724057A/en unknown
- 2015-03-19 RS RS20181363A patent/RS57970B1/sr unknown
- 2015-03-19 CN CN201580014506.0A patent/CN106102734B/zh active Active
- 2015-03-19 HR HRP20181914TT patent/HRP20181914T1/hr unknown
- 2015-03-19 DK DK15714132.6T patent/DK3119384T3/en active
- 2015-03-19 KR KR1020167025636A patent/KR102000332B1/ko active Active
- 2015-03-19 US US14/663,027 patent/US9486428B2/en active Active
- 2015-03-19 PT PT15714132T patent/PT3119384T/pt unknown
- 2015-03-19 PL PL15714132T patent/PL3119384T3/pl unknown
- 2015-03-19 EP EP15714132.6A patent/EP3119384B1/en active Active
- 2015-03-19 UA UAA201609525A patent/UA120756C2/uk unknown
-
2016
- 2016-08-31 ZA ZA2016/06043A patent/ZA201606043B/en unknown
- 2016-09-08 PH PH12016501769A patent/PH12016501769A1/en unknown
- 2016-09-15 CL CL2016002338A patent/CL2016002338A1/es unknown
- 2016-09-19 IL IL247920A patent/IL247920B/en active IP Right Grant
- 2016-09-21 US US15/271,460 patent/US9808436B2/en active Active
-
2017
- 2017-09-29 US US15/720,849 patent/US10220011B2/en active Active
-
2018
- 2018-11-28 CY CY181101264T patent/CY1120927T1/el unknown
- 2018-12-17 US US16/222,325 patent/US10828273B2/en active Active
-
2020
- 2020-10-03 US US17/062,545 patent/US11406611B2/en active Active
-
2025
- 2025-07-31 LT LTPA2025529C patent/LTPA2025529I1/lt unknown
- 2025-07-31 FI FIC20253004C patent/FIC20253004I1/fi unknown
- 2025-08-01 NO NO2025035C patent/NO2025035I1/no unknown
- 2025-08-05 FR FR25C1031C patent/FR25C1031I2/fr active Active
- 2025-08-13 HU HUS2500033C patent/HUS2500033I1/hu unknown
- 2025-08-13 NL NL301338C patent/NL301338I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| PH12016501769B1 (en) | Treatment of intrahepatic cholestatic diseases | |
| IL253795A0 (en) | Methods for treating cancer using activated t cells | |
| IL253244B1 (en) | Methods for treating retinal diseases | |
| PT3212233T (pt) | Terapia combinada para o tratamento de doenças | |
| PH12016501978A1 (en) | Treatment of nafld and nash | |
| PL3851537T3 (pl) | Leczenie hiperbilirubinemii | |
| HUE041940T2 (hu) | MRNS-terápia szembetegségek kezelésére | |
| GB201701673D0 (en) | Methods of well treatment | |
| MX392537B (es) | Tratamiento del prurito colestasico. | |
| EP3185884A4 (en) | Combination therapy for treatment of cancer | |
| TW201613587A (en) | Medical treatments based on anamorelin | |
| IL253847A0 (en) | Methods of treating diseases | |
| IL246558A0 (en) | Novel methods for treating cancer | |
| EP3383449A4 (en) | IMPLANTABLE KIDNEY THERAPY THERAPY | |
| GB201416832D0 (en) | Methods of treatment | |
| GB201408297D0 (en) | Treatment of cancer | |
| GB201407837D0 (en) | Methods of cancer therapy | |
| PL3903774T3 (pl) | N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych | |
| GB201417456D0 (en) | Treatment of cancer | |
| PT3851537T (pt) | Tratamento da hiperbilirrubinemia | |
| GB201409362D0 (en) | Treatment of cancer | |
| GB201405449D0 (en) | Treatment of cancer | |
| GB201405075D0 (en) | Treatment of cancer |